


INFECTIONS IN TRANSPLANT PATIENTS

Dr Clementine Fraser – Respiratory and
Transplant physician



Infections in transplant patients

Leading cause of problems especially in first year.

Clinical manifestations can be few or atypical in immunocompromised hosts

Eg. 40% of infection cause no fever

Many of the pathogens are uncommon in immunocompetent individuals

Important to try to get exact diagnosis so correct decisions can be made about treatment

Drug interactions a significant aspect of decisions about treatment (immunosuppression etc.)

Element renal decline.


Different Types of Infection

Bacterial Infections


Viruses

Fungus

Timeline of Common Post-Transplant Infections



- Donor (fluid/ BAL)
- Ventilator – positive pressure/ tubes etc.
- Immunosuppressive therapy – more immunosuppressed for 3 months. Higher aims
- Procedures / lines - (leaks/fluid collections/poor wound healing) - Urinary/Vascular/Dialysis catheters, surgical drains,
- Wounds - breaks in skin/mucosae
- Lung slightly more than heart
- Lungs not sterile
- Open to elements
- RATG (aggressive immunosuppressant early on)



Common Sites


- Chest
- Urine (UTI)
- Skin (cellulitis)
- Bowel
- Sternum
- Line (eg. dialysis)



+

•

○



Chest Infections / Pneumonia

- Interchangeable
- Pneumonia – changes on CXR
- Sputum
- Fever
- Send off sample
- Bloods/CXR
- Spirometry (lung)


Targeting treatment




SPUTUM CULTURES



WHAT GROWN BEFORE



WHAT RADIOLOGY AND
BLOODS LOOK LIKE



Covid (Virus)

- Cough cold fever
- Lateral flow
- Swab
- Early might be eligible for medications that reduce severity

Molnupiravir

Sotrovimab


Paxlovid (nirmatrelvir / ritonavir combination), **should not be** used in transplant recipients due to the significant interaction with calcineurin inhibitor (Tac) and mTOR (siro).

Remdesivir

IL-6 inhibitors (Tocilizumab and Sarilumab, Sotrovimab)

Keep lateral flows at home

Urinary Tract Infections



Diarrhoea

Normal flora disrupted. Immunosuppression.

Microbiome

Norovirus

C difficile

CMV

Table 1. Common causes of post-transplant diarrhea

Infectious	Noninfectious
Bacterial <i>Clostridium difficile</i> <i>Campylobacter</i> spp. <i>Salmonella</i> spp. Bacterial overgrowth <i>Aeromonas</i> spp. <i>Escherichia coli</i>	IS medications Mycophenolate Tacrolimus Cyclosporine Sirolimus
Viruses CMV Norovirus Sapovavirus Rotavirus Adenovirus	Non-IS medications Antibacterial Antiarrhythmic Antidiabetic Laxatives Proton pump inhibitors Protease inhibitors
Parasitic <i>Giardia</i> <i>Cryptosporidium</i> <i>Isospora</i> <i>Cyclospora</i> <i>Microsporidium</i>	Other GVHD PTLD IBD Colon cancer

- Send sample
- Stay hydrated – protect kidneys
- May need treatment depending on cause

Sternum Osteomyelitis (bacteria)



Weeping

Crunching/
clicking
Instability

Swab



CMV

- CMV is a common virus that is usually harmless in the immunocompetent population.
- **VALGANCICLOVIR**
 - Neutropenia, nephrotoxicity
- **FOSCARNET**
 - Nephrotoxicity
- **MARIBAVIR**
- **Risk Factors - Who is most at risk?**

CMV

Donor-Recipient Serological Mismatch:

D+/R- (Donor positive, Recipient negative):

Intensive Immunosuppression:

Longer Ischemic Time:

Type and Duration of Prophylaxis:

Premature Discontinuation of Antivirals:

+

•

○



Varicella

- Contact has chicken pox/shingles
 - If direct contact or if unsure, advise full varicella tx
 - Same day prescription of aciclovir 400mg 5x daily for 7-10 days
 - If develop rash they must contact transplant centre; disseminated Zoster can be serious may need IV aciclovir/ steroids
 - Eligible for Shingrix vaccine

EBV associated PTLD

- Post-transplantation lymphoproliferative disorder (PTLD) is a widely recognized complication of transplantation.
- Uncontrolled growth of B lymphocytes –
- Fever, weight loss, night sweats, fatigue, and Lymphadenopathy
- The incidence of PTLD rare
- Primary Epstein-Barr virus (EBV) infection is a major risk factor as well as immunosuppression.
- Patients who were EBV- before lung transplant are more likely to develop PTLD
- Ix - CT CAP if suspect – **EBV DNA copies**






Fig. 11—Posttransplantation lymphoproliferative disorder (PTLD) in 26-year-old man 4 months after bilateral lung transplantation.
A, Multiple lung nodules were detected incidentally on surveillance chest radiograph.
B, CT scan shows multiple nodules with surrounding halo of ground glass (arrows). Percutaneous CT-guided biopsy confirmed diagnosis of PTLD.

Fungi and transplant

- **Lung or disseminated (eg. in blood)**
In lungs initially likes to sit on the joins and the sutures
- **Colonisation**
 - Tx candidates – Pre transplant (eg. CF or bronchiectasis patients for lungs)
 - *Aspergillus* spp most common (*A. fumigatus* 59%, *A. flavus* 35%)
- **Invasive fungal infection post-Tx**
 - Rates 3-14%
 - Why on prophylaxis



Risk factors:

Colonisation before/early after Tx
Acute/chronic rejection
CMV infection
Single lung tx
Airway stents
Diabetes

PcP - *Pneumocystis* *jirovecii*

Pneumocystis jirovecii is a ubiquitous and opportunistic fungus that is localized in the alveoli.

Dyspnoea and/or non-productive cough, drop in LF

Lifelong prophylaxis is required for tx patients.

Agents – most co-trimoxazole.



Mitigating risk



VACCINATION –
PNEUMOCOCCAL,
COVID, INFLUENZA ,
SHINGLES, RSV



SENSIBLE IN CROWDED
PLACES



ACTIVE



EARLY INTERVENTION/
CONTACT



TAKING PROPHYLAXIS
WHERE APPROPRIATE/
SUITABLE

Prophylaxis

Aciclovir, Valganciclovir or Ganciclovir 3 months or 6 in D+/R- CMV, CMV viremia monitored for regularly.

Co-trimoxazole - PCP prophylaxis for life PCP

Azithromycin (also reduces rejection but is a good antibiotic too).

Antifungals – 100 days Nystatin

Vaccinations – influenza, pneumococcal, covid 19